Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.
$294.05 0.56 (0.19)%
Market Cap 31.15B
05/25/18 2:19 PM ET | Minimum 20 minutes delay.
Stock information provided by eSignal.
Barclays 2018 Biopharmaceuticals CEO/CFO Conference Call Series
Jun 1, 2018 | 11:00 AM ET
2018 Annual Meeting of Shareholders
Jun 8, 2018 | 10:30 AM ET